Caladrius Biosciences Inc. (NASDAQ: CLBS) Jumps 4.5% After FDA Approves Its CLBS201 IND in Diabetic Kidney Disease

June 29, 2021

Caladrius Biosciences Inc. (NASDAQ: CLBS) climbed 4.46% after the FDA approved its Investigational New Drug Application for the CLBS201 study. CLBS201 is a CD34+ cell therapy for diabetic kidney disease treatment.  Caladrius evaluating CLBS20’s efficacy and safety  David J. Mazzo, the company’s CEO and President said, “Our latest development program, CLBS201, is designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic patients with…

Read More >>